Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-001 with Cocaine in Cocaine Use Disorder
NCT02856854Phase 1Completed
- Sponsor
- Embera NeuroTherapeutics
- Start
- Jul 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cocaine use disorder (CUD) comparing EMB-001 Sequence with Placebo Sequence (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 29 Days, Vital signs at 29 days and 1 more. Started Jul 2016; status: completed.
02
Drugs
metyrapone + oxazepam
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT02856854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856854.